FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129136311> ?p ?o ?g. }

• W2129136311 endingPage "1912" @default.
• W2129136311 startingPage "1905" @default.
• W2129136311 abstract "<h3>Objective</h3> Lynch syndrome is caused by germline mutations in DNA mismatch repair genes leading to microsatellite instability (MSI) and colorectal cancer. Mesalazine, commonly used for the treatment of UC, reduces MSI in vitro. Here, we tested natural compounds for such activity and applied mesalazine and thymoquinone in a Msh2^loxP/loxP Villin-Cre mouse model for Lynch syndrome. <h3>Design</h3> Flow cytometry was used for quantitation of mutation rates at a CA₁₃ microsatellite in human colon cancer (HCT116) cells that had been stably transfected with pIREShyg2-enhanced green fluorescent protein/CA13, a reporter for frameshift mutations. Mice were treated for 43 weeks with mesalazine, thymoquinone or control chow. Intestines were analysed for tumour incidence, tumour multiplicity and size. MSI testing was performed from microdissected normal intestinal or tumour tissue, compared with mouse tails and quantified by the number of mutations per marker (NMPM). <h3>Results</h3> Besides mesalazine, thymoquinone significantly improved replication fidelity at 1.25 and 2.5 µM in HCT116 cells. In Msh2^loxP/loxP Villin-Cre mice, tumour incidence was reduced by mesalazine from 94% to 69% (p=0.04) and to 56% (p=0.003) by thymoquinone. The mean number of tumours was reduced from 3.1 to 1.4 by mesalazine (p=0.004) and to 1.1 by thymoquinone (p<0.001). Interestingly, MSI was reduced in normal intestinal tissue from 1.5 to 1.2 NMPM (p=0.006) and to 1.1 NMPM (p=0.01) by mesalazine and thymoquinone, respectively. Thymoquinone, but not mesalazine, reduced MSI in tumours. <h3>Conclusions</h3> Mesalazine and thymoquinone reduce tumour incidence and multiplicity in Msh2^loxP/loxP Villin-Cre mice by reduction of MSI independent of a functional mismatch repair system. Both substances are candidate compounds for chemoprevention in Lynch syndrome mutation carriers." @default.
• W2129136311 created "2016-06-24" @default.
• W2129136311 creator A5006583038 @default.
• W2129136311 creator A5008041667 @default.
• W2129136311 creator A5008317857 @default.
• W2129136311 creator A5012576635 @default.
• W2129136311 creator A5021628637 @default.
• W2129136311 creator A5024917921 @default.
• W2129136311 creator A5044427732 @default.
• W2129136311 creator A5055058026 @default.
• W2129136311 creator A5061537270 @default.
• W2129136311 creator A5068669060 @default.
• W2129136311 creator A5076344113 @default.
• W2129136311 creator A5082053382 @default.
• W2129136311 date "2014-11-26" @default.
• W2129136311 modified "2023-09-25" @default.
• W2129136311 title "Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2^loxP/loxPVillin-Cre mice" @default.
• W2129136311 cites W1504535992 @default.
• W2129136311 cites W1533529053 @default.
• W2129136311 cites W1984323762 @default.
• W2129136311 cites W1997799520 @default.
• W2129136311 cites W2004566532 @default.
• W2129136311 cites W2005471609 @default.
• W2129136311 cites W2020889440 @default.
• W2129136311 cites W2024513902 @default.
• W2129136311 cites W2029607349 @default.
• W2129136311 cites W2030232289 @default.
• W2129136311 cites W2030565050 @default.
• W2129136311 cites W2035475717 @default.
• W2129136311 cites W2052993162 @default.
• W2129136311 cites W2056926264 @default.
• W2129136311 cites W2062059313 @default.
• W2129136311 cites W2065973208 @default.
• W2129136311 cites W2068906373 @default.
• W2129136311 cites W2076364680 @default.
• W2129136311 cites W2079621764 @default.
• W2129136311 cites W2087090420 @default.
• W2129136311 cites W2092868004 @default.
• W2129136311 cites W2094390470 @default.
• W2129136311 cites W2101677946 @default.
• W2129136311 cites W2107810966 @default.
• W2129136311 cites W2109265894 @default.
• W2129136311 cites W2114784947 @default.
• W2129136311 cites W2121293908 @default.
• W2129136311 cites W2121538983 @default.
• W2129136311 cites W2122346321 @default.
• W2129136311 cites W2123977467 @default.
• W2129136311 cites W2124540388 @default.
• W2129136311 cites W2125859388 @default.
• W2129136311 cites W2127753323 @default.
• W2129136311 cites W2137537116 @default.
• W2129136311 cites W2138075385 @default.
• W2129136311 cites W2141760501 @default.
• W2129136311 cites W2150587328 @default.
• W2129136311 cites W2156780879 @default.
• W2129136311 cites W2157304020 @default.
• W2129136311 cites W2157477464 @default.
• W2129136311 cites W2162901424 @default.
• W2129136311 cites W2165606389 @default.
• W2129136311 cites W2171896334 @default.
• W2129136311 cites W2296049797 @default.
• W2129136311 doi "https://doi.org/10.1136/gutjnl-2014-307663" @default.
• W2129136311 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4680183" @default.
• W2129136311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25429050" @default.
• W2129136311 hasPublicationYear "2014" @default.
• W2129136311 type Work @default.
• W2129136311 sameAs 2129136311 @default.
• W2129136311 citedByCount "21" @default.
• W2129136311 countsByYear W21291363112015 @default.
• W2129136311 countsByYear W21291363112016 @default.
• W2129136311 countsByYear W21291363112017 @default.
• W2129136311 countsByYear W21291363112018 @default.
• W2129136311 countsByYear W21291363112020 @default.
• W2129136311 countsByYear W21291363112021 @default.
• W2129136311 countsByYear W21291363112022 @default.
• W2129136311 countsByYear W21291363112023 @default.
• W2129136311 crossrefType "journal-article" @default.
• W2129136311 hasAuthorship W2129136311A5006583038 @default.
• W2129136311 hasAuthorship W2129136311A5008041667 @default.
• W2129136311 hasAuthorship W2129136311A5008317857 @default.
• W2129136311 hasAuthorship W2129136311A5012576635 @default.
• W2129136311 hasAuthorship W2129136311A5021628637 @default.
• W2129136311 hasAuthorship W2129136311A5024917921 @default.
• W2129136311 hasAuthorship W2129136311A5044427732 @default.
• W2129136311 hasAuthorship W2129136311A5055058026 @default.
• W2129136311 hasAuthorship W2129136311A5061537270 @default.
• W2129136311 hasAuthorship W2129136311A5068669060 @default.
• W2129136311 hasAuthorship W2129136311A5076344113 @default.
• W2129136311 hasAuthorship W2129136311A5082053382 @default.
• W2129136311 hasBestOaLocation W21291363111 @default.
• W2129136311 hasConcept C121608353 @default.
• W2129136311 hasConcept C126322002 @default.
• W2129136311 hasConcept C153911025 @default.
• W2129136311 hasConcept C2778004101 @default.
• W2129136311 hasConcept C2779034068 @default.
• W2129136311 hasConcept C2779115348 @default.
• W2129136311 hasConcept C502942594 @default.
• W2129136311 hasConcept C526805850 @default.

• next